CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 885 participants.
Also called NCT05681351
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 885 participants
- Sponsor
- Registry
-
NCT05681351
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Slovakia, South Africa, Spain, Sweden, Taiwan, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05681351. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-13 (actual); primary completion 2027-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- Olezarsen
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct05681351- Content hash
ab3340695f5706ef09aea2edf21e27513a0a29e3c1cc1fccf393141762dfe694